{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T11:13:29Z","timestamp":1789298009825,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40258-025-00968-7","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T10:24:53Z","timestamp":1745490293000},"page":"649-660","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-Effectiveness and Value of Information Analyses of Caplacizumab for the Treatment of Thrombotic Thrombocytopenic Purpura in Brazil"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-7294","authenticated-orcid":false,"given":"Julia","family":"Sim\u00f5es Correa Galendi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1483-1015","authenticated-orcid":false,"given":"Hannes","family":"Rasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0390-1061","authenticated-orcid":false,"given":"Carlos Antonio","family":"Caramori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9480-4995","authenticated-orcid":false,"given":"Rafael Dezen","family":"Gaiolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5576-0192","authenticated-orcid":false,"given":"Dirk","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-4167","authenticated-orcid":false,"given":"Vania Santos Nunes","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"3","key":"968_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12185-023-03552-8","volume":"117","author":"M Kubo","year":"2023","unstructured":"Kubo M, Matsumoto M. Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura (in eng). Int J Hematol. 2023;117(3):331\u201340. https:\/\/doi.org\/10.1007\/s12185-023-03552-8.","journal-title":"Int J Hematol"},{"issue":"7","key":"968_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1538-7836.2005.01436.x","volume":"3","author":"DR Terrell","year":"2005","unstructured":"Terrell DR, Williams LA, Vesely SK, L\u00e4mmle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency (in eng). J Thromb Haemost. 2005;3(7):1432\u20136. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01436.x.","journal-title":"J Thromb Haemost"},{"key":"968_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1137019","volume":"10","author":"S Selvakumar","year":"2023","unstructured":"Selvakumar S, Liu A, Chaturvedi A. Immune thrombotic thrombocytopenic purpura: spotlight on long-term outcomes and survivorship (in Eng). Front Med (Lausanne). 2023;10: 1137019. https:\/\/doi.org\/10.3389\/fmed.2023.1137019.","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"968_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260196","volume":"16","author":"A Renaud","year":"2021","unstructured":"Renaud A, et al. Deleterious neurological impact of diagnostic delay in immune-mediated thrombotic thrombocytopenic purpura (in eng). PLoS ONE. 2021;16(11): e0260196. https:\/\/doi.org\/10.1371\/journal.pone.0260196.","journal-title":"PLoS ONE"},{"key":"968_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxae167","author":"S Xing","year":"2024","unstructured":"Xing S, Bullano M, Hale S, Lokhandwala T, Murty S. Clinical and economic burden of suspected thrombotic thrombocytopenic purpura in US hospitals (in eng). Am J Health Syst Pharm. 2024. https:\/\/doi.org\/10.1093\/ajhp\/zxae167.","journal-title":"Am J Health Syst Pharm"},{"key":"968_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2202850","author":"J He","year":"2023","unstructured":"He J, et al. Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis (in eng). Expert Rev Hematol. 2023. https:\/\/doi.org\/10.1080\/17474086.2023.2202850.","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"968_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (in eng). N Engl J Med. 2019;380(4):335\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1806311.","journal-title":"N Engl J Med"},{"issue":"10","key":"968_CR8","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","volume":"18","author":"XL Zheng","year":"2020","unstructured":"Zheng XL, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura (in eng). J Thromb Haemost. 2020;18(10):2496\u2013502. https:\/\/doi.org\/10.1111\/jth.15010.","journal-title":"J Thromb Haemost"},{"key":"968_CR9","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria - ANVISA. \"Cablivi\u00ae (caplacizumabe): novo registro.\" Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria\u2014ANVISA. https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/novos-medicamentos-e-indicacoes\/cablivi-r-caplacizumabe-novo-registro. Accessed 11 May 2023."},{"issue":"6","key":"968_CR10","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00277-023-05211-8","volume":"102","author":"T de Oliveira Boechat","year":"2023","unstructured":"de Oliveira Boechat T, de Holanda Farias JS, Ribeiro EFO, de Andrade MLL. Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program (in eng). Ann Hematol. 2023;102(6):1581\u20138. https:\/\/doi.org\/10.1007\/s00277-023-05211-8.","journal-title":"Ann Hematol"},{"key":"968_CR11","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. \"Diretrizes metodol\u00f3gicas: estudos de avalia\u00e7\u00e3o econ\u00f4mica de tecnologias em sa\u00fade 132 p. : il.\" Minist\u00e9rio da Sa\u00fade. (accessed 2. ed. )."},{"issue":"2","key":"968_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.clinthera.2022.01.011","volume":"44","author":"D Husereau","year":"2022","unstructured":"Husereau D, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations (in eng). Clin Ther. 2022;44(2):158\u201368. https:\/\/doi.org\/10.1016\/j.clinthera.2022.01.011.","journal-title":"Clin Ther"},{"issue":"10","key":"968_CR13","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jval.2023.06.014","volume":"26","author":"N Kunst","year":"2023","unstructured":"Kunst N, et al. Consolidated health economic evaluation reporting standards\u2014value of information (CHEERS-VOI): explanation and elaboration. Value Health. 2023;26(10):1461\u201373. https:\/\/doi.org\/10.1016\/j.jval.2023.06.014.","journal-title":"Value Health"},{"issue":"3","key":"968_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","volume":"158","author":"M Scully","year":"2012","unstructured":"Scully M, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies (in eng). Br J Haematol. 2012;158(3):323\u201335. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09167.x.","journal-title":"Br J Haematol"},{"issue":"4","key":"968_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/bjh.19026","volume":"203","author":"M Scully","year":"2023","unstructured":"Scully M, et al. A British Society for Haematology Guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies (in eng). Br J Haematol. 2023;203(4):546\u201363. https:\/\/doi.org\/10.1111\/bjh.19026.","journal-title":"Br J Haematol"},{"key":"968_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2023.11.006","author":"POC Terra","year":"2023","unstructured":"Terra POC, De Santis GC, Prado J\u00fanior BPA, Oliveira LC. Outcomes of thrombotic thrombocytopenic purpura patients submitted to therapeutic plasma exchange in a single center in Brazil (in eng). Hematol Transfus Cell Ther. 2023. https:\/\/doi.org\/10.1016\/j.htct.2023.11.006.","journal-title":"Hematol Transfus Cell Ther."},{"issue":"12","key":"968_CR17","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1111\/jth.15892","volume":"20","author":"M Scully","year":"2022","unstructured":"Scully M, et al. Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: post-HERCULES study (in eng). J Thromb Haemost. 2022;20(12):2810\u201322. https:\/\/doi.org\/10.1111\/jth.15892.","journal-title":"J Thromb Haemost"},{"issue":"12","key":"968_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.21037\/atm-22-2847","volume":"10","author":"B Chen","year":"2022","unstructured":"Chen B, Li X, Xiao D, Raimundo RD, Zhou R, Lei Y. Comparison of the efficacy and safety of caplacizumab versus placebo in thrombotic thrombocytopenic purpura: a meta-analysis and systematic review based on randomized controlled trials (in eng). Ann Transl Med. 2022;10(12):657. https:\/\/doi.org\/10.21037\/atm-22-2847.","journal-title":"Ann Transl Med"},{"issue":"1","key":"968_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/jha2.833","volume":"5","author":"N Neupane","year":"2024","unstructured":"Neupane N, et al. Does Caplacizumab for the management of thrombotic thrombocytopenic purpura increase the risk of relapse, exacerbation, and bleeding? An updated systematic review and meta-analysis based on revised criteria by the International Working Group for thrombotic thrombocytopenic purpura (in eng). EJHaem. 2024;5(1):178\u201390. https:\/\/doi.org\/10.1002\/jha2.833.","journal-title":"EJHaem"},{"issue":"9","key":"968_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272290","volume":"17","author":"JTS de Castro","year":"2022","unstructured":"de Castro JTS, et al. Neurological manifestations in thrombotic microangiopathy: imaging features, risk factors and clinical course (in eng). PLoS ONE. 2022;17(9): e0272290. https:\/\/doi.org\/10.1371\/journal.pone.0272290.","journal-title":"PLoS ONE"},{"issue":"7","key":"968_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199593","volume":"13","author":"MA Pappas","year":"2018","unstructured":"Pappas MA, Vijan S, Rothberg MB, Singer DE. Reducing age bias in decision analyses of anticoagulation for patients with nonvalvular atrial fibrillation\u2014a microsimulation study (in eng). PLoS ONE. 2018;13(7): e0199593. https:\/\/doi.org\/10.1371\/journal.pone.0199593.","journal-title":"PLoS ONE"},{"key":"968_CR22","doi-asserted-by":"publisher","first-page":"S469","DOI":"10.1016\/j.jval.2018.09.2766","volume":"21","author":"D Burns","year":"2018","unstructured":"Burns D, et al. Psy192-patient health-related quality of life associated with remission of Attp, a regression analysis using non-randomised observational data from the Oklahoma TTP REGISTRY. Value Health. 2018;21:S469.","journal-title":"Value Health"},{"issue":"7","key":"968_CR23","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3324\/haematol.2019.226423","volume":"105","author":"S Riva","year":"2020","unstructured":"Riva S, et al. Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura (in eng). Haematologica. 2020;105(7):1957\u201362. https:\/\/doi.org\/10.3324\/haematol.2019.226423.","journal-title":"Haematologica"},{"issue":"2","key":"968_CR24","doi-asserted-by":"publisher","first-page":"22s","DOI":"10.11606\/s1518-8787.2017051007134","volume":"51","author":"BO Ascef","year":"2017","unstructured":"Ascef BO, et al. Health-related quality of life of patients of Brazilian primary health care (in eng por). Rev Saude Publica. 2017;51(2):22s. https:\/\/doi.org\/10.11606\/s1518-8787.2017051007134.","journal-title":"Rev Saude Publica"},{"issue":"1","key":"968_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12955-021-01671-6","volume":"19","author":"M Santos","year":"2021","unstructured":"Santos M, Monteiro AL, Santos B. EQ-5D Brazilian population norms (in eng). Health Qual Life Outcomes. 2021;19(1):162. https:\/\/doi.org\/10.1186\/s12955-021-01671-6.","journal-title":"Health Qual Life Outcomes"},{"key":"968_CR26","unstructured":"DATASUS. Sistema de Informa\u00e7\u00f5es Hospitalares do SUS. https:\/\/datasus.saude.gov.br\/transferencia-de-arquivos\/. Accessed."},{"key":"968_CR27","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. \"Contas do SUS na perspectiva da contabilidade internacional: Brasil, 2010-2014,\" F. O. Cruz, Ed., ed: Minist\u00e9rio da Sa\u00fade Bras\u00edlia, 2018."},{"key":"968_CR28","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria - ANVISA. Listas de pre\u00e7os de medicamentos. https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/cmed\/precos. Accessed 15 Aug 2024."},{"key":"968_CR29","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. \"O uso de limiares de custo-efetividade nas decis\u00f5es em sa\u00fade: Recomenda\u00e7\u00f5es da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS.\" Minist\u00e9rio da Sa\u00fade. https:\/\/www.gov.br\/conitec\/pt-br\/midias\/pdf\/2022\/20221106_relatorio-uso-de-limiares-de-custo-efetividade-nas-decisoes-em-saude.pdf. Accessed."},{"issue":"6","key":"968_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","volume":"15","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20136 (in eng). Value Health. 2012;15(6):835\u201342. https:\/\/doi.org\/10.1016\/j.jval.2012.04.014.","journal-title":"Value Health"},{"issue":"4","key":"968_CR31","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1524-4733.2009.00686.x","volume":"13","author":"JJ Barendregt","year":"2010","unstructured":"Barendregt JJ. The effect size in uncertainty analysis (in eng). Value Health. 2010;13(4):388\u201391. https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00686.x.","journal-title":"Value Health"},{"issue":"2","key":"968_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jval.2020.01.001","volume":"23","author":"E Fenwick","year":"2020","unstructured":"Fenwick E, et al. Value of information analysis for research decisions-an introduction: report 1 of the ISPOR value of information analysis emerging good practices task force (in eng). Value Health. 2020;23(2):139\u201350. https:\/\/doi.org\/10.1016\/j.jval.2020.01.001.","journal-title":"Value Health"},{"issue":"3","key":"968_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/0272989x13505910","volume":"34","author":"M Strong","year":"2014","unstructured":"Strong M, Oakley JE, Brennan A. Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach (in eng). Med Decis Mak. 2014;34(3):311\u201326. https:\/\/doi.org\/10.1177\/0272989x13505910.","journal-title":"Med Decis Mak"},{"key":"968_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/jbm.S464365","volume":"15","author":"P Du","year":"2024","unstructured":"Du P, Cristarella T, Goyer C, Moride Y. A systematic review of the epidemiology and disease burden of congenital and immune-mediated thrombotic thrombocytopenic purpura (in eng). J Blood Med. 2024;15:363\u201386. https:\/\/doi.org\/10.2147\/jbm.S464365.","journal-title":"J Blood Med"},{"key":"968_CR35","unstructured":"\"CADTH Common Drug Reviews\". In: CADTH Canadian Drug Expert Committee Recommendation: Caplacizumab (Cablivi\u2014Sanofi-Aventis Canada Inc.): Indication: For the treatment of adults with acquired thrombotic thrombocytopenic purpura. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health Copyright \u00a9 2020 Canadian Agency for Drugs and Technologies in Health. 2020."},{"key":"968_CR36","unstructured":"National institute for Health and Care Excellence (NICE). Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (Technology appraisal guidance TA667.). 2020."},{"issue":"7","key":"968_CR37","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1182\/blood.2020006052","volume":"137","author":"G Goshua","year":"2021","unstructured":"Goshua G, Sinha P, Hendrickson JE, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura (in eng). Blood. 2021;137(7):969\u201376. https:\/\/doi.org\/10.1182\/blood.2020006052.","journal-title":"Blood"},{"key":"968_CR38","unstructured":"Conselho Nacional de Sa\u00fade. \"Brasil. Resolu\u00e7\u00e3o CNS n\u00ba 563, de 10 de novembro de 2017.\" https:\/\/www.gov.br\/conselho-nacional-de-saude\/pt-br\/acesso-a-informacao\/legislacao\/resolucoes\/2017\/resolucao-no-563.pdf. Accessed."},{"key":"968_CR39","unstructured":"Sa\u00fade BM. Diretrizes metodol\u00f3gicas: estudos de avalia\u00e7\u00e3o econ\u00f4mica de tecnologias em sa\u00fade 132 p. : il.\" Minist\u00e9rio da Sa\u00fade. (accessed 2. ed.)."},{"key":"968_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05771-3","author":"O Mulas","year":"2024","unstructured":"Mulas O, et al. Long-term health-related quality of life and mental health in patients with immune thrombotic thrombocytopenic purpura (in eng). Ann Hematol. 2024. https:\/\/doi.org\/10.1007\/s00277-024-05771-3.","journal-title":"Ann Hematol"},{"issue":"4","key":"968_CR41","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/jamainternmed.2022.6787","volume":"183","author":"C Pham","year":"2023","unstructured":"Pham C, Le K, Draves M, Seoane-Vazquez E. Assessment of FDA-approved drugs not recommended for use or reimbursement in other countries, 2017\u20132020 (in Eng). JAMA Intern Med. 2023;183(4):290\u20137. https:\/\/doi.org\/10.1001\/jamainternmed.2022.6787.","journal-title":"JAMA Intern Med"},{"key":"968_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12154887","author":"A Butt","year":"2023","unstructured":"Butt A, Allen C, Purcell A, Ito S, Goshua G. Global health resource utilization and cost-effectiveness of therapeutics and diagnostics in immune thrombotic thrombocytopenic purpura (TTP) (in Eng). J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12154887.","journal-title":"J Clin Med"},{"issue":"3","key":"968_CR43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jtha.2022.11.010","volume":"21","author":"LA V\u00f6lker","year":"2023","unstructured":"V\u00f6lker LA, et al. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura (in Eng). J Thromb Haemost. 2023;21(3):559\u201372. https:\/\/doi.org\/10.1016\/j.jtha.2022.11.010.","journal-title":"J Thromb Haemost"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-025-00968-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-025-00968-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T05:52:28Z","timestamp":1750053148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-025-00968-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["968"],"URL":"https:\/\/doi.org\/10.1007\/s40258-025-00968-7","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"7 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: Julia Sim\u00f5es Corr\u00eaa Galendi and Dirk M\u00fcller; Methodology: Julia Sim\u00f5es Corr\u00eaa Galendi and Dirk M\u00fcller; Formal analysis and investigation: Julia Sim\u00f5es Corr\u00eaa Galendi and Hannes Rasch; Model Validation: Rafael Dezen Gaiolla, Dirk M\u00fcller, Vania Santos Nunes Nogueira; Writing \u2013 original draft preparation: Julia Sim\u00f5es Corr\u00eaa Galendi and Dirk M\u00fcller; Writing \u2013 review and editing: Julia Sim\u00f5es Corr\u00eaa Galendi, Hannes Rasch, Carlos Antonio Caramori, Rafael Dezen Gaiolla, Dirk M\u00fcller, Vania Santos Nunes Nogueira; Funding acquisition: Carlos Antonio Caramori, and Vania Santos Nunes Nogueira; Resources: Vania Santos Nunes Nogueira; Supervision: Vania Santos Nunes Nogueira.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This research was conducted based on publicly available data and therefore no ethical approval is required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. Partial financial support was received from the Coordination for the Improvement of Higher Education Personnel \u2013 Brazil (CAPES), CAPES-PESQUISA-CLINICA program.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Data used in the development of this model is publicly available. The model file in Trex format can be made available upon inquiry to the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The Trex model used in this study was provided to the journal\u2019s peer reviewers for their reference when reviewing the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}